The Department of Medicine at Mayo Clinic in Rochester announced recipients of its 2020 Coronavirus Research Initiative. Research grants to study the spread, manifestations and outcomes of infection were awarded by the Department of Medicine and Mayo Clinic Center for Clinical and Translational Science.
Michael Barry, Ph.D. (INFD ’06), Division of Infectious Diseases, Mayo Clinic
University of Minnesota collaborator: David Masopust, Ph.D.
Nathan Cummins, M.D. (TRANSM '08, NEPH '09, INFD '11, CTSA '14), "HIV Protease Inhibitors to Decrease Apoptosis Due to the Novel Coronavirus"
Division of Infectious Diseases
Richard Kennedy, Ph.D. (INFD '03, I '06), "Evaluating Humoral Immune Responses to SARS-CoV-2"
Division of General Internal Medicine; Department of Immunology; Vaccine Research Group
Joseph Murray, M.D. (GI '98), "Do ACE Inhibitors, Angiotensin II Type 1 Receptor Blockers and/or Ibuprofen Upregulate ACE2 on the Intestinal Epithelium?"
Division of Gastroenterology and Hepatology; Department of Immunology
Sanjeev Nanda, M.D. (GIM '13), "Prevalence of Obesity and Multimorbidity in the Novel Coronavirus-Infected Patients and the Risk of Long-Term Outcomes"
Division of General Internal Medicine
Robert Vassallo, M.D. (I '98, THDC '01), "Cigarette Smoking and Sex as Modulators of Lung Epithelial ACE2 Expression in COVID-19 Infection"
Division of Pulmonary and Critical Care Medicine; Department of Physiology and Biomedical Engineering
Thomas Witzig, M.D. (HEM '86), "Pre-clinical testing of a Potent CRM1 Inhibitor on Coronavirus to Provide Rationale for a Clinical Trial"
Division of Hematology; Department of Laboratory Medicine and Pathology
Hemang Yadav, M.B.B.S. (I '13, CI '14, CTSA '16, THDC '16), "Biomarker Titrated Corticosteroid Dosing for SARS-CoV-2: A Randomized Controlled Trial"
Division of Pulmonary and Critical Care Medicine